Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation
Pharmacopsychiatry · 01.01.2025 · 58 (01) · 5-13
DOI: 10.1055/a-2446-6877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.01.2025. Verfasst von Jan Haeckert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Neuropsychological Tests, Antiparkinson Agents. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study evaluates the impact of Parkinson disease (PD) medication in advanced PD on neuropsychological performance, psychiatric symptoms, impulsivity and the quality of life. In the 4-year period 27 patients with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean age: 58.9±7.1, disease duration: 10.0 years±4.2) were examined preoperatively. We hypothesized that a high dosage of PD medication or current use of dopamine agonists affect cognitive functioning and psychiatric wellbeing.
Methods
We performed two subgroup analyses with low versus high levodopa-equivalent Dosage (LED) medication and without versus with dopaminagonistic medication.
Results
The neuropsychological testing revealed significant differences in the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500, Z=− 2.475, p=0.012) and in the subtest of the semantic fluency of Regensburg verbal fluency test (RWT) (t(25)=− 2.066, p=0.049) with better results for patients without dopaminagonistic medication. Pearson correlation analyses of LED in correlation with the clinical and cognitive dependent variables showed a significant higher PANSS total score in patients with higher LED medication (r=0.491, p=0.009). In addition, lower LED treatment was associated with significant higher scores in the impulsivity perseverance subtest (r=− 0.509, p=0.008).
Discussion
In conclusion, we found lower LEDs to be correlated with a better perseverance in the impulsivity test and additional treatment with a dopamine agonist influenced some verbal learning tasks and the PANSS total score in patients with advanced PD. This should be considered prior to DBS surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Augsburg, Germany.
- Department of Psychiatry and Psychotherapy, University Hospital Munich, LMU Munich, München, Germany.
- Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Translational Brain Research, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
- DZPG (German Center for Mental Health), partner site Munich/Augsburg, Germany.
Zitieren
APA
Haeckert, J., Roeh, A., Karch, S., Koeglsperger, T., Hasan, A., & Papazova, I. (2025). Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. Pharmacopsychiatry, 58(01), 5-13. https://doi.org/10.1055/a-2446-6877
Vancouver
Haeckert J, Roeh A, Karch S, Koeglsperger T, Hasan A, Papazova I. Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. Pharmacopsychiatry. 2025;58(01):5-13. doi:10.1055/a-2446-6877
BibTeX
@article{Haeckert2025,
author = {Haeckert, Jan and Roeh, Astrid and Karch, Susanne and Koeglsperger, Thomas and Hasan, Alkomiet and Papazova, Irina},
title = {Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation},
journal = {Pharmacopsychiatry},
year = {2025},
volume = {58},
number = {01},
pages = {5--13},
doi = {10.1055/a-2446-6877}
}
EUVIMED